CALL US

Blog

Integration Update: Expanded FAQ for Advarra Merger Efforts

The Advarra team (formerly Chesapeake IRB and Schulman IRB) continues to integrate our processes and policies, leveraging mutual strengths in technology, regulatory expertise and customer service to provide clients with high quality research reviews and unparalleled efficiencies. The following FAQ expands upon previous FAQs we’ve published and provides additional insight into the integration process. We’ve […]

READ MORE

PRIM&R’s Ampersand Blog Features Advarra Colleague, Dr. Derrick Aarons

Dr. Derrick Aarons, ethicist for the Caribbean Public Health Agency (CARPHA) and founding president of the Bioethics Society of the English-Speaking Caribbean (BSEC), discusses the future of bioethics in the Caribbean, in a recent Ampersand article.

READ MORE

International Research and Research Ethics Review

Clinical research continues to grow throughout the world, with researchers looking outside the US for new and diverse subject populations to help develop and improve investigational therapies. Requirements for research ethics review vary considerably country to country, and the regulatory variety can be daunting for a researcher new to working outside the purview of US […]

READ MORE

Integration Update: Revised FAQ for Advarra Merger Efforts

Since November 2017, the Advarra team (formerly Chesapeake IRB and Schulman IRB) has been working to integrate our processes and policies, leveraging mutual strengths in technology, regulatory expertise and customer service to provide clients with high quality research reviews and unparalleled efficiencies. In the last few months we’ve made a lot of progress, and we’ve […]

READ MORE

Most Popular Blogs of 2017

As 2017 draws to a close, we invite you to take a look back at Schulman’s most popular blog posts from this year. To create this list, we used website data to determine the 2017 blogs with the largest readership audience. Revisit a favorite topic or discover something new from our blog. Have an idea […]

READ MORE

Schulman IRB and Chesapeake IRB Merger and Integration: What You Need to Know

On November 7, 2017, we announced that Chesapeake IRB and Schulman IRB are merging under the new organizational name, Advarra. Our teams are excited to work with a like-minded organization and for the new opportunities this merger offers, and the overwhelmingly positive response we’ve received from the research community thus far reaffirms our confidence in […]

READ MORE

Changes to NIH Policy for Issuing Certificates of Confidentiality: What You Need to Know

On October 1, 2017, NIH’s policy for certificates of confidentiality (CoCs) changed so that CoCs are now automatically issued for all NIH-funded research that collects or uses identifiable, sensitive information. Previously, CoCs were issued by NIH on request and only for research that involved information that, if disclosed, could have adverse consequences for subjects or […]

READ MORE

“Significant Risk” and “Nonsignificant Risk” Determinations for Medical Devices

In medical device research, the determination of “significant risk” or “nonsignificant risk” can sometimes be confusing, especially for those new to device research. Unique to the device space, this risk determination is not the same as a “no more than minimal risk” determination. Let’s take a closer look at what significant risk (SR) and nonsignificant […]

READ MORE